The study has two main parts. The first part aims to find the right dose of ubamatamab when given alone or with cemiplimab by checking how safe it is and how the body processes the medication. The second part looks at how well these treatments work in shrinking or controlling the cancer. For patients with ovarian, fallopian tube, or primary peritoneal cancer, they must have received at least one previous treatment with platinum-based chemotherapy and have cancer that has returned or is no longer responding to treatment. For patients with endometrial cancer, they must have previously received treatment with a type of immune therapy and platinum-based chemotherapy, and their cancer must show a certain protein marker called MUC16 in at least one quarter of the tumor cells.

During the study, patients will receive their assigned treatment and be monitored regularly for side effects and to see how their cancer responds. Doctors will use scans and blood tests to check if the cancer is shrinking, staying the same, or growing. The study will also measure how the treatment affects quality of life and daily functioning through questionnaires. Blood samples will be taken to measure the amount of medication in the body and to check if the body develops any reaction to the medications. The study will continue until enough information is gathered about the safety and effectiveness of these treatments.

The purpose of the study is to evaluate how well these treatments work in maintaining the health of patients with platinum-sensitive recurrent ovarian cancer. This means the cancer has responded to platinum-based chemotherapy in the past but has come back. The study will compare the effects of sacituzumab tirumotecan with or without bevacizumab against the standard care, which may include observation or the use of bevacizumab. Participants will receive these treatments through an intravenous infusion, which means the medication is given directly into a vein.

The study will be conducted in two parts. The first part will focus on assessing the safety and how well patients tolerate the treatment. The second part will compare the effectiveness of the treatments in preventing the cancer from getting worse. The study will last for a period of up to 84 days, during which participants will be closely monitored for any side effects and the overall impact on their health. The goal is to find out if these treatments can help improve the quality of life and extend the time patients remain free from cancer progression.

The purpose of the study is to determine how effective olaparib is in maintaining the health of patients after their cancer has progressed, compared to the standard chemotherapy options. Participants in the study will receive either olaparib or one of the standard chemotherapy treatments after undergoing a surgical procedure known as secondary cytoreductive surgery, which aims to remove as much of the cancer as possible.

The study will follow participants over a period of time to observe their progression-free survival, which means the length of time during and after treatment that a patient lives with the disease without it getting worse. The study will also look at overall survival, safety, and quality of life. Participants will be randomly assigned to receive either olaparib or one of the standard chemotherapy treatments, and some may receive a placebo. The study is designed to provide valuable information on the best treatment options for patients with recurrent ovarian cancer.

The purpose of the study is to explore how well Olaparib works in patients with this specific type of ovarian cancer. Participants in the study will take Olaparib tablets by mouth. The study will monitor how long patients remain free from cancer progression, as well as their overall survival and response to the treatment. The study will also look at any side effects experienced by the participants.

This trial is expected to continue until 2027. It aims to provide valuable information about the effectiveness of Olaparib in treating recurrent ovarian cancer in patients without BRCA1 and BRCA2 mutations. The findings could help improve treatment options for this group of patients in the future.

The purpose of the study is to explore the safety and effectiveness of these treatments. Participants will receive the medications in the form of film-coated tablets taken orally. The study is divided into two phases. In the first phase, the focus is on determining the safe dosage levels of ZN-c3 when used with Niraparib. The second phase aims to assess how well these treatments work in reducing the cancer. The study will also look at the effects of ZN-c3 when used alone, examining both its safety and its ability to fight the cancer.

Throughout the study, participants will be monitored for any side effects and the overall impact of the treatment on their cancer. The study will help researchers understand the potential benefits and risks of using ZN-c3 and Niraparib together or ZN-c3 alone in treating Platinum-Resistant Ovarian Cancer. This research is important for developing new treatment options for patients with this challenging form of cancer.

The purpose of the study is to find the best way to use these treatments, either alone or together, to help patients with LGSOC. The study is divided into different parts. In the first part, researchers will determine whether Avutometinib alone or in combination with Defactinib is more effective. In the following parts, they will further evaluate the effectiveness of the chosen treatment plan. The study will also explore if a lower dose of Avutometinib combined with Defactinib is effective.

Participants in the study will receive either Avutometinib alone or in combination with Defactinib. The study will monitor how well the cancer responds to the treatment and any side effects that may occur. The study aims to provide valuable information on the potential benefits of these treatments for patients with LGSOC.

Participants in the study will receive one of several possible treatments, which include medications such as Palbociclib, Capecitabine, Niraparib, Doxorubicin Hydrochloride, Topotecan, Paclitaxel, Sacituzumab Govitecan, Fulvestrant, Carboplatin, Docetaxel, Vinorelbine, Olaparib, Bevacizumab, Cyclophosphamide, and Etoposide. Some patients may receive a placebo, which is a substance with no active medication. The study will last for a maximum of 24 months, during which the effectiveness of the treatments will be monitored.

The main goal of the study is to see if the zAvatar-test can better predict which treatments will work best for patients, helping to improve their progression-free survival, which means the length of time during and after treatment that a patient lives with the disease without it getting worse. The study will also look at other outcomes, such as the overall survival of patients and their response to the treatments. This research could lead to more personalized and effective treatment options for patients with these types of cancer.

Participants in the study will receive either the new treatment combination or a standard treatment, which may include drugs like Gemcitabine, Paclitaxel, Doxorubicin, Rucaparib, Olaparib, or Niraparib. Some participants may receive a placebo. The study will monitor the time it takes for the cancer to progress or for the patient to pass away, whichever happens first. This is known as progression-free survival. The study will also look at overall survival, which is the time from the start of the study until death from any cause, and the response rate, which measures how well the cancer responds to the treatment.

The trial will last for several years, and participants will be closely monitored throughout the study. The study aims to provide valuable information about the potential benefits and risks of using Mirvetuximab soravtansine with Carboplatin in treating recurrent ovarian cancer. This research could lead to new treatment options for patients with this type of cancer.

The purpose of this study is to determine if pembrolizumab, when used in combination with chemotherapy, can help patients with this type of cancer live longer without the disease getting worse. Participants in the study will receive the treatment and be monitored over a period of time to see how well the cancer responds. The study will also look at the safety of the treatment and how it affects the quality of life for those involved.

Throughout the study, participants will receive pembrolizumab through an intravenous infusion, which means the medication is given directly into a vein. The study will last for several months, and participants will have regular check-ups to monitor their health and the progress of the treatment. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the treatment. The study aims to provide valuable information on the potential benefits of pembrolizumab for patients with low-grade serous ovarian cancer.

Participants in this study will receive pertuzumab, and possibly trastuzumab, through an intravenous (IV) infusion, which means the medication is delivered directly into the bloodstream through a vein. The study is designed to monitor the safety and effectiveness of the treatment over time. Patients will be observed for any adverse events, which are unwanted effects that may occur during treatment. The study will also assess how long patients live without their cancer getting worse, known as progression-free survival, and overall survival, which is the length of time patients live after starting the treatment.

This study is an extension of a previous trial, meaning it continues the treatment for patients who were already receiving pertuzumab and were benefiting from it. The trial is open-label, which means both the researchers and participants know which treatment is being administered. The study aims to provide ongoing access to pertuzumab for those who need it, ensuring that patients continue to receive the potential benefits of the therapy.

The purpose of the study is to evaluate how well these treatments work in patients with recurrent ovarian cancer. Participants in the study will receive either the ADP-A2M4CD8 treatment alone or in combination with nivolumab. The treatments are given through an infusion, which means they are delivered directly into the bloodstream. The study will monitor the participants over a period to see how their cancer responds to the treatment and to check for any side effects.

This trial is open-label, meaning both the researchers and participants know which treatment is being administered. The study aims to provide valuable information on the effectiveness and safety of using genetically modified T cells, both alone and with nivolumab, in treating recurrent ovarian cancer. Participants will be closely monitored throughout the study to ensure their safety and to gather data on the treatment’s impact on their cancer.

The purpose of this study is to determine the best dose of these medications when used together and to evaluate how well they work in treating the cancers mentioned. The study is divided into two phases: the Dose Escalation Phase and the Dose Expansion Phase. In the Dose Escalation Phase, researchers will focus on finding the safest and most effective dose of the medications. In the Dose Expansion Phase, they will look at how well the treatment works in a larger group of patients. Participants in the study may receive either the combination of REGN5668 with Cemiplimab or REGN5668 with REGN4018.

Throughout the study, participants will receive the medications through an intravenous infusion, which means the drugs are given directly into a vein. The study will monitor the participants for any side effects and measure how the cancer responds to the treatment. The trial aims to provide valuable information on the potential benefits of these new treatment combinations for patients with these specific types of cancer.

Participants in the study will receive treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will last for up to 24 months, during which time patients will be monitored regularly. The study aims to see how well the treatments work in stopping the cancer from progressing, as well as to observe any side effects and overall survival rates. The study will also assess the impact of the treatments on patients’ quality of life, including their general health and any symptoms related to the abdomen and gastrointestinal tract.

This trial is designed to provide valuable information on the potential benefits and risks of using these medications in combination for treating platinum-resistant recurrent ovarian cancer. By comparing different treatment combinations, the study hopes to find more effective ways to manage this challenging condition. Participants will be closely monitored by healthcare professionals throughout the study to ensure their safety and well-being.

The study is divided into two parts. In the first part, participants will receive DS-3939a to assess its safety and how well it is tolerated by the body. In the second part, the study will continue to evaluate safety and also measure the treatment’s effectiveness at a recommended dose. This will involve looking at how the cancer responds to the treatment, which is known as the objective response rate. Participants may have different types of advanced cancers, including those of the lung, breast, ovary, and pancreas, among others.

Throughout the study, participants will be closely monitored for any side effects or changes in their health. This includes regular check-ups, laboratory tests, and imaging studies to track the progress of the treatment. The study aims to gather important information that could lead to new treatment options for people with advanced solid tumors. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of DS-3939a.

The main purpose is to determine how effective these maintenance treatments are in preventing cancer progression in patients who have responded to platinum-based chemotherapy. The study will last up to 24 months, during which patients may receive either TEDOPI as an injection under the skin, pembrolizumab as an infusion into a vein, a combination of both treatments, or supportive care.

TEDOPI is a type of treatment called a cancer vaccine that helps the body’s immune system fight cancer cells. Pembrolizumab is a medication that works by helping the immune system detect and attack cancer cells. Both treatments are designed to strengthen the body’s natural defenses against cancer.